Law 360 M&A

JANUARY 2, 2024

and Myovant Sciences Ltd. have escaped for good a proposed class action alleging the companies' merger was undervalued because the lawyers from Skadden Arps Slate Meagher & Flom LLP who helped negotiate the deal had undisclosed conflicts of interest. Sumitomo Pharma America Inc.

52

52

Benzinga

OCTOBER 23, 2022

Myovant Sciences, Inc. NYSE: MYOV ) announced late Sunday a deal to be acquired by Japanese pharmaceutical company Sumitomo Pharma Co., Ltd's (OTC: DNPUF ) unit Sumitovant Biopharma. The Deal Terms: The agreement provides for all of the Myovant shares to be acquired at $27 per share in cash, or $1.7

75

75

Benzinga

OCTOBER 3, 2022

Myovant Sciences Ltd (NYSE: MYOV ) rejected a $2.5 billion takeover offer from Sumitovant Biopharma Ltd and Sumitomo Pharma Co., Ltd, saying that the offer undervalues the company. to acquire the remaining shares of the Company that Sumitovant does not currently hold for a price of $22.75 Sumitovant.

52

52

Law 360 M&A

OCTOBER 11, 2023

Two firms have been named lead counsel for a proposed class action against Myovant Sciences Ltd. and Sumitomo Pharma America Inc.

40

40

Law 360 M&A

SEPTEMBER 14, 2023

Pharmaceutical companies Myovant Sciences Ltd. and Sumitomo Pharma American Inc.

40

40

Law 360 M&A

OCTOBER 3, 2022

Stock in Swiss-based Myovant Sciences Ltd. jumped nearly 37% Monday after the biopharmaceutical company announced it had rejected as too low a $2.5 billion enterprise value offer from Japanese company and majority shareholder Sumitovant Biopharma Ltd.

Enterprise Value 40

Enterprise Value 40

Benzinga

OCTOBER 23, 2022

Sumitovant Biopharma to Acquire all Outstanding Shares of Myovant for $27 Per Share in Cash. Agreement Unanimously Recommended by Special Committee of Myovant's Independent Directors and Approved by Board. 23, 2022 (GLOBE NEWSWIRE) -- Sumitovant Biopharma Ltd. 23, 2022 (GLOBE NEWSWIRE) -- Sumitovant Biopharma Ltd.

40

40